Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C

Clinical Infectious Diseases

Volumn 51, Issue 5, 2010, Pages 541-549

  Liu, Chen Hua ^a,b,c   Liang, Cheng Chao ^d   Liu, Chun Jen ^a,b,c   Lin, Jou Wei ^c   Chen, Shih I ^c   Hung, Peir Haur ^e   Tsai, Hung Bin ^f   Lai, Ming Yang ^a,b,c   Chen, Pei Jer ^a,b,c   Chen, Ding Shinn ^a   Kao, Jia Horng ^a,b,c,f  

^a Department of Internal Medicine ^*  (Taiwan)

^b Hepatitis Research Center   (United States)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^e CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^f BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; VIRUS RNA;

ACUTE HEPATITIS; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DERMATITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; GENOTYPE; HEADACHE; HEMODIALYSIS PATIENT; HEPATITIS C; HUMAN; INJECTION SITE REACTION; INSOMNIA; IRRITABILITY; LEUKOPENIA; MALE; MULTICENTER STUDY; MYALGIA; PRIORITY JOURNAL; RIGOR; SIDE EFFECT; THROMBOCYTOPENIA; TOGAVIRUS; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

EID: 84984548713     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/655682     Document Type: Article

References (40)

1. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002; 36:3-10.
2. Martin P, Fabrizi F. Hepatitis C virus and kidney disease. J Hepatol 2008; 49:613-24.
3. Laporte F, Tap G, Jaafar A, et al. Mathematical modeling of hepatitis C virus transmission in hemodialysis. Am J Infect Control 2009; 37: 403-7.
4. Okuda K, Hayashi H, Yokozeki K, Kobayashi S, Kashima T, Irie Y. Acute hepatitis C among renal failure patients on chronic haemodialysis. J Gastroenterol Hepatol 1998; 13:62-7.
5. Espinosa M, Martin-Malo A, Alvarez de Lara MA, Gonzalez R, Rodriguez M, Aljama P. Natural history of acute HCV infection in hemodialysis patients. Clin Nephrol 2002; 58:143-50.
6. Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000; 11:1896-902.
7. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther 2004; 20:1271-7.
8. Bruchfeld A, Stahle L, Andersson J, et al. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection-a pilot study. J Viral Hepat 2001; 8:287-92.
9. Rendina M, Schena A, Castellaneta NM, et al. The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 2007; 46: 768-74.
10. Liu CH, Liang CC, Liu CJ, et al. Pegylated interferon alfa-2a plus low dose ribavirin for the retreatment of dialysis chronic hepatitisCpatients who relapsed from prior interferon monotherapy. Gut 2009; 58:314-6.
11. Cammà C, Almasio P, Craxì A. Interferon as treatment for acute hepatitis C: a meta-analysis. Dig Dis Sci 1996; 41:1248-55.
12. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24:778-89.
13. Jaeckel E, Cornberg M, Wedemeyer H, et al; German Acute Hepatitis C Therapy Group. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345:1452-7.
14. Nomura H, Sou S, Tanimoto H, et al. Short-term interferon alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology 2004; 39:1213-9.
15. Delwaide J, Bourgeois N, Gérard C, et al; Belgian Association for the Study of the Liver. Treatment of acute hepatitis C with interferon alpha- 2b: early initiation of treatment is the most effective predictive factor of sustained viral response. Aliment Pharmacol Ther 2004; 20:15-22.
16. Wiegand J, Buggisch P, Boecher W, et al; German HEP-NET Acute HCV Study Group. Early monotherapy with pegylated interferon alpha- 2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 2006; 43:250-6.
17. Kamal SM, Moustafa KN, Chen J, et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology 2006; 43: 923-31.
18. Santantonio T, Fasano M, Sinisi E, et al. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol 2005; 42: 329-33.
19. De Rosa FG, Bargiacchi O, Audagnotto S, et al. Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C. J Antimicrob Chemother 2006; 57:360-3.
20. Calleri G, Cariti G, Gaiottino F, et al. A short course of pegylated interferon-alpha in acute HCV hepatitis. J Viral Hepat 2007; 14:116-21.
21. Santantonio T, Medda E, Ferrari C, et al. Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. Clin Infect Dis 2006; 43:1154-9.
22. Kamal SM, Fouly AE, Kamel RR, et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 2006; 130:632-8.
23. Corey KE, Mendez-Navarro J, Gorospe EC, Zheng H, Chung RT. Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis. J Viral Hepat 2010; 17:201-7.
24. Gürsoy M, Gür G, Arslan H, Ozdemir N, Boyacioglu S. Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment. J Viral Hepat 2001; 8: 70-7.
25. Urbánek P, Tesar V, Procházková-Francisci E, Lachmanová J, Marecek Z, Svobodník A. Treatment of early diagnosed HCV infection in hemodialyzed patients with interferon-alpha: treatment of hepatitis C. Blood Purif 2004; 22:344-50.
26. Al-Harbi AS, Malik GH, Subaity Y, Mansy H, Abutaleb N. Treatment of acute hepatitis C virus infection with alpha interferon in patients on hemodialysis. Saudi J Kidney Dis Transpl 2005; 16:293-7.
27. Rocha CM, Perez RM, Narciso JL, et al. Interferon-alpha therapy within the first year after acute hepatitis C infection in hemodialysis patients: efficacy and tolerance. Eur J Gastroenterol Hepatol 2007; 19:119-23.
28. Engel M, Malta FM, Gomes MM, et al. Acute hepatitis C virus infection assessment among chronic hemodialysis patients in the Southwest Parana State, Brazil. BMC Public Health 2007; 7:50.
29. Liu CH, Liang CC, Lin JW, et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut 2008; 57:525-30.
30. Potthoff A, Wiegand J, Lüth JB, Wedemeyer H, Manns MP, Tillmann HL. Superiority of standard interferon-alpha2b compared to pegylated interferon-alpha2b (12 kDa) in a hemodialysis patient with chronic hepatitis C? Clin Nephrol 2005; 63:232-5.
31. Hung KY, Lee KC, Yen CJ, Wu KD, Tsai TJ, Chen WY. Revised cutoff values of serum aminotransferase in detecting viral hepatitis among CAPD patients: experience from Taiwan, an endemic area for hepatitis B. Nephrol Dial Transplant 1997; 12:180-3.
32. Mizuno M, Higuchi T, Yanai M, Kanmatsuse K, Esumi M. Dialysismembrane- dependent reduction and adsorption of circulating hepatitis C virus during hemodialysis. Nephron 2002; 91:235-42.
33. Lamb TW, Marks IM,Wynohradnyk L, ModiMW, Preston RA, Pappas SC. 40 kDa Peginterferon alfa-2a (Pegasys@) can be administered safety in patients with end-stage renal disease. Hepatology 2001; 34:326A.
34. Lemos LB, Perez RM, Matos CA, Silva IS, Silva AE, Ferraz ML. Clinical and laboratory characteristics of acute hepatitis C in patients with end-stage renal disease on hemodialysis. J Clin Gastroenterol 2008; 42: 208-11.
35. McGovern BH, Birch CE, Bowen MJ, et al. Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. Clin Infect Dis 2009; 49:1051-60.
36. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194:1395-406.
37. Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288:339-44.
38. Liu CH, Chen BF, Chen SC, Lai MY, Kao JH, Chen DS. Selective transmission of hepatitis C virus quasi species through a needlestick accident in acute resolving hepatitis. Clin Infect Dis 2006; 42:1254-9.
39. McGovern BH, Nagami EH, Birch CE, et al. Rate of sustained virologic response in relation to baseline hepatitis C virus (HCV) RNA level and rapid virologic clearance in persons with acute HCV infection. J Infect Dis 2009; 200:877-81.
40. Santantonio T, Sinisi E, Guastadisegni A, et al. Natural course of acute hepatitis C: a long-term prospective study. Dig Liver Dis 2003; 35: 104-13.